What is claraT ?
claraT is a unique software-driven solution, classifying biologically relevant gene expression signatures into a comprehensive, easy-to-interpret report.
The claraT * Report
claraT classifies multiple publicly available gene expression signatures and single gene targets linked to multiple key biologies, alongside Almac’s own proprietary assays, according to the 10 Hallmarks of Cancer.
Clients are provided with a unique, interactive report that allows the easy visualisation of the key discriminating biologies within either a large cohort or an individual tumour sample.
A pan-cancer solution, based on a powerful bioinformatics pipeline, automatically generating the claraT report from raw gene expression data utilising the Almac optimised RNA Exome Panel.
* Note: claraT is for research use only (RUO) and is not to be used for diagnostic or prognostic purposes, including predicting responsiveness to a particular therapy.
Initial claraT Report – Facts:
- 3 key biologies
- 35 unique gene expression signatures
- 30 single gene drug targets
- 1,641 single genes relevant to launch content
claraT Report outputs:
Comprehensive cohort and individual sample reports, summarised signature scores and summarised gene expression for single targets
Gene expression raw data file:
Raw data files provided as part of Almac’s optimised RNA Exome Panel.
First conceptualised by Douglas Hanahan and Robert Weinberg in 2000 and subsequently updated in 2011, the Hallmarks of Cancer have become a paradigm within modern cancer research.
The hallmarks help explain the complexity of cancer cells and describe the processes that occur allowing cancer cells to proliferate and grow if unchecked.
The claraT report utilises the Hallmarks of Cancer concept of targetable biologies to help facilitate biomarker discovery. claraT embodies the tenets set out by the authors, intelligently simplifying the complex biologies of cancer within key hallmarks.